Nutrient use efficiency company Verdesian Life Sciences, Cary, N.C., on June 18 announced the appointment of Wendy Shusko as Chief Financial Officer. In her role, Shusko will oversee corporate finance, financial planning and analysis, tax, accounting, internal audit, and risk management.
“We’re excited that Wendy has joined the Verdesian team,” said Verdesian CEO Clare Doyle. “Wendy’s leadership and expertise will be a major asset to us as we continue to grow our business globally.”
Shusko brings more than 35 years of financial experience to Verdesian, most recently serving as CEO and CFO of STATinMED, a life sciences data and insight organization. She began her career with Shire Pharma, holding multiple financial leadership roles before becoming President and CEO of WellSpring Pharmaceutical. She also serves as board member of privately held Sheffield Pharmaceuticals. Shusko attended the University of North Carolina Wilmington and Rutgers University, studying accounting. She will be based out of the company’s Cary office.
Verdesian has made other recent changes to its executive leadership team. In March the company promoted Sergio Melloni to the role of Vice President, South America and Latin America, and added Avinash (Avi) Deshmukh as Vice President, Global Marketing. Also in March, Sudhir Shinde was appointed Vice President, EMEA and Asia Pacific.
Melloni joined Verdesian in 2018 and previously served as Managing Director, South America, with earlier roles at Monsanto and Novozymes. Deshmugh held prior roles at Cyanamid India, BASF, and UPL, while Shinde was formerly with UPL and held prior roles at Monsanto, FMC, Novozymes, and Sumitomo Chemicals.